Zobrazeno 1 - 10
of 11
pro vyhledávání: '"MJ Sánchez Garre"'
Autor:
S Vicente Sánchez, MJ Sánchez Garre, L Menéndez Naranjo, M Almanchel Rivadeneyra, A Tomás Luiz, M Valderrey Pulido
Publikováno v:
Drug information and pharmacotherapy.
Background The development of direct acting antiviral agents (DAAs) represents a significant improvement in hepatitis C virus (HCV) treatment, particularly in allowing interferon free therapy. HIV coinfection is common, with genotypes 1 and 4 being t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::889a273b31369a6316683b40ac19d80d
https://doi.org/10.1136/ejhpharm-2017-000640.266
https://doi.org/10.1136/ejhpharm-2017-000640.266
Autor:
MJ Sánchez Garre, R. Pla Poblador, M.A. Rosado Souvirón, Carlos Rubio-Terrés, C. Martínez Nieto, J.P. Ordovás Baines
Publikováno v:
Farmacia Hospitalaria. 31:78-92
Objective: To analyse the use of health care resources and the associated costs in patients with rheumatoid arthritis (RA) treated with three biological disease-modifying anti-rheumatic drugs (bDMARDs): etanercept, infliximab and adalimumab. Method:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e80c7f448561f7cd6c54e35dfebc0765
https://doi.org/10.1016/s1130-6343(07)75718-5
https://doi.org/10.1016/s1130-6343(07)75718-5
Autor:
MJ Sánchez Garre, A Mancebo González, A De la Rubia Nieto, L Menéndez Naranjo, M Almanchel Rivadeneyra, MC Muñoz Contreras
Publikováno v:
European Journal of Hospital Pharmacy. 23:A126.2-A127
Background Dolutegravir has been marketed in Spain since last year. It is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV infected adults and adolescents >12 years of age. Due to its recent approval, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1aa5fbc20cfa067b09da4c8cedcbc7ed
https://doi.org/10.1136/ejhpharm-2016-000875.287
https://doi.org/10.1136/ejhpharm-2016-000875.287
Autor:
MJ Sánchez Garre, S Vicente Sánchez, A De la Rubia Nieto, MC Muñoz Contreras, L Menéndez Naranjo, M Almanchel Rivadeneyra
Publikováno v:
European Journal of Hospital Pharmacy. 23:A14.2-A15
Background The development of direct acting antiviral agents (DAAs) represents a significant improvement in hepatitis C virus (HCV) treatment. Interferon free combinations such as sofosbuvir (SOF) plus daclatasvir (DAC) have become available this yea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68f809ed7c78ec425f9132adbf9b843d
https://doi.org/10.1136/ejhpharm-2016-000875.33
https://doi.org/10.1136/ejhpharm-2016-000875.33
Autor:
M Almanchel Rivadeneyra, S Vicente Sánchez, MJ Sánchez Garre, L Menéndez Naranjo, MC Muños Contreras, ADe la Rubio Nieto
Publikováno v:
European Journal of Hospital Pharmacy. 23:A12.2-A13
Background The development of direct acting antiviral agents (DAAs) represents a significant improvement in hepatitis C virus (HCV) treatment, particularly to allow interferon free therapy. It is important to decide which treatment is best suited to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f93309bfdc38d5b7273733b4a0312e2
https://doi.org/10.1136/ejhpharm-2016-000875.28
https://doi.org/10.1136/ejhpharm-2016-000875.28
Autor:
MM Galindo Rueda, MJ Sánchez Garre, A De la Rubia Nieto, MA Fernandez de Palencia Espinosa, V Arocas Casañ, S Vicente Sánchez, L Menéndez Naranjo
Publikováno v:
European Journal of Hospital Pharmacy. 22:A19.2-A20
Background In Spain, the authorised indications for botulinum toxin type A (BTTA, Botox) are: Neurological diseases: focal spasticity (foot, wrist and hand, ankle), blepharospasm, hemifacial spasm and associated focal dystonias, cervical dystonia and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::701b25ad6c27081df44fbcf8cf785690
https://doi.org/10.1136/ejhpharm-2015-000639.46
https://doi.org/10.1136/ejhpharm-2015-000639.46
Autor:
J Mateo Carmona, C Ramirez Roig, L Menéndez Naranjo, MJ Sánchez Garre, M Almanchel Rivadeneyra
Publikováno v:
European Journal of Hospital Pharmacy. 22:A155.1-A155
Background Alternative treatments (AT) such as homeopathy (H) and/or medicinal herbs (MH) a r e used concomitantly with medical treatment by some patients to relieve and/or improve the symptoms of a disease. Pharmaceutical care consultations (PCC) ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a75e3eb8cee5b9de80dd0a704756f897
https://doi.org/10.1136/ejhpharm-2015-000639.373
https://doi.org/10.1136/ejhpharm-2015-000639.373
Publikováno v:
Farmacia Hospitalaria. 31:254-255
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d57ee3b6438c00431b68001c05f2a93b
https://doi.org/10.1016/s1130-6343(07)75384-9
https://doi.org/10.1016/s1130-6343(07)75384-9
Autor:
MJ Sánchez Garre, MA Fernandez de Palencia, C Ramirez Roig, J Mateo Carmona, A De la Rubia Nieto, Diaz Carrasco, L Menéndez Naranjo
Publikováno v:
European Journal of Hospital Pharmacy. 20:A210.1-A210
Background In recent years, many oral antineoplastic agents (OAAs) have appeared providing patient convenience. According to law, in the Autonomous Community of Region de Murcia (Spain), these drugs are dispensed at hospital pharmacies in the outpati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83ea560a86209daf2fc204e455da7a54
https://doi.org/10.1136/ejhpharm-2013-000276.582
https://doi.org/10.1136/ejhpharm-2013-000276.582
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2007 Jul-Aug; Vol. 31 (4), pp. 254-6.